With all of the recent news around a new treatment for Alzheimer's disease (AD), the huge gains by smaller biotechs developing treatments can get lost. The excitement is understandable. There have been 130 failed attempts to bring an AD treatment to market since 1998.
Now that the Food and Drug Administration has approved Biogen 's (NASDAQ: BIIB) Aduhelm despite its mixed results, it theoretically made it much easier for new treatments to get the green light.
That anticipation -- and positive early results -- are why shares of Annovis Bio (NYSEMKT: ANVS) and Cassava Sciences (NASDAQ: SAVA) are both up more than 1,000% so far this year. They each offer a new way for treating Alzheimer's that has shown promising results. Those novel approaches could be the path to profits for investors willing to buy shares while the future is still uncertain.
For further details see:
These 2 Biotech Stocks Are Up 1,000% This Year